What Happened?
San Francisco, CA-based 89bio Appointed Rohan Palekar as Chief Executive Officer
About the Company
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
About the Person
Rohan Palekar is Chief Executive Officer at 89bio. Previously, Rohan held various senior HR leadership roles in the industry.
Info Source
News
Short Profile